Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (Nasdaq:FURX) relating to the proposed acquisition by Forest Laboratories, Inc.

Click here to learn more about the investigation, or call: 877-534-2590. There is no cost or obligation to you.

Under the terms of the transaction, Furiex shareholders will receive only $95.00 in cash and a Contingent Value Right of up to $30.00 in cash, that may be payable based upon the FDA status of eluxadoline, for each share of Furiex stock they own. The investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Furiex for not acting in the Company’s shareholders’ best interests in connection with the sale process. The transaction may undervalue Furiex and is below the premium paid in comparable transactions. For example, Furiex stock traded at $113.55 on February 5, 2014 and an analyst has set a $140.00 per share price target on Furiex.

If you own shares of Furiex common stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at, by visiting, or calling toll free 877-LEGAL-90.

Brodsky & Smith, LLC is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and case action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

Copyright Business Wire 2010